Safety and Clinical Performance of a Biological Matrix Used in Implant-based Breast Reconstruction

The general objective of the study is to confirm the medium/long-term safety and clinical performance of the CELLIS Breast membranes used in breast reconstruction and to identify emerging risks in comparison to clinical data related to other treatment modalities. The present study will be a prospective, multicentric, non-randomized and non-controlled trial involving 112 patients followed for 24 months. The study will be conducted in France in 7 investigational centres.

Inclusion Criteria: * Patient aged ≥18 years, * Patient with an indication of breast reconstruction after mastectomy (therapeutic or prophylactic), * Patient being informed of her participation to the study and of the follow-up visits, and having no objection to the clinical data collection and medical file access, * Patient being informed of the porcine origin of the device in advance of the procedure. Exclusion Criteria: * Patient with known hypersensitivity to porcine materials, * Patient with an existing infection at the site of implantation, * Patient having refused to participate to the study, * Patient refusing to return for the follow-up visits, * Patient who is pregnant.